Spiffy Unveils Recall Capture, First End-to-End Recall Automation Platform for Mobile Repairs
RESEARCH TRIANGLE PARK, NC / ACCESS Newswire / May 6, 2025 / Spiffy®, the mobile service technology company trusted by leading dealership groups and OEMs, today announced the beta launch of Recall Capture™, the first end-to-end recall automation platform purpose-built for mobile repairs.
As the latest addition to Spiffy's Mobile 360™ platform, Recall Capture streamlines the entire recall cycle - from VIN detection and customer outreach to automated scheduling and route-optimized van dispatch. Its proprietary VIN prioritization engine pinpoints recalls best suited for mobile service, helping dealerships close more recalls, free up bays for higher-margin work, and improve CSI without adding BDC headcount.
Beta Testing With Top Dealer Groups
In limited beta with several of the nation's top dealer groups, Recall Capture is already helping service teams streamline scheduling, reach customers who postpone in-store visits, and capture service revenue that often goes unclaimed.
"Recall volume is at an all-time high, yet workflows haven't kept pace," said Karl Murphy, Spiffy Co-founder and CEO. "Recall Capture gives fixed ops teams an automated path to mobile completions, turning compliance into revenue. It's built on over a decade of mobile service innovation that helps dealers grow fixed ops revenue while improving retention and CSI."
Closing the Gap Between Outreach and Completion
Most dealerships detect recalls digitally, but completions stall when customers must visit the store. Recall Capture removes this barrier by embedding mobile repair from the start - customers self-schedule at home or work, and Mobile 360 will assign and dispatch technicians without tying up bays.
"We're not just building another recall tool; we're reimagining what mobile-first fixed ops can look like," said Ryan Eade, Spiffy CTO and Head of Product. "Recall Capture brings together detection, outreach, scheduling, and repair in one seamless system that dealers can actually use at scale. It's the result of years of boots-on-the-ground experience, now wrapped into one unified product."
The Capture™ Roadmap
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
New Balance's 'Comfortable' Fresh Foam Hiking Shoes Are Already $44 Off
The Arena Media Brands, LLC and respective content providers may receive compensation for some links to products and services on this website. New Balance's 'Comfortable' Fresh Foam Hiking Shoes Are Already $44 Off originally appeared on Athlon Sports. Outdoor enthusiasts, take notice. You can score a good deal right now on a pair of New Balance Fresh Foam X Hierro Hiker Shoes, which the athletic retailer describes as "an easy-wearing, waterproof hiker with grippy treads and cushioned midsole for year-round exploration." Normally $190, New Balance is offering this newer model for 23% off, now down to $146. Sizes range from US men's 7 to 16 and US women's 5 to 13, and wide sizes are also available. The available color, pictured below, is "SHIPYARD with DOCKSIDE and Sea Salt." New Balance Reviews: What Are Customers Saying? These hybrid hikers don't have a ton of buyer reviews quite yet, but the early returns are positive, with an overall rating of 4.8 stars out of 5.0. Here is what a few shoppers have said online: "Great Hiking Shoe. Very comfortable, with great support." "They fit good and look good. Have received multiple compliments wanting to know where I got them." "Very comfortable and good for long hikes on uneven terrain." Fresh Foam X Hierro Hiker Shoes, $146 (Was $190) at New Balance More Product and Shipping Details In addition to its "incredible comfort," New Balance's website highlights that the "GORE-TEX® waterproof fabric protects feet from wind, rain and water without sacrificing breathability." These also offer Toe Protect technology, which helps shield your feet from "rocks, roots and debris" as you soak in the trails. Free shipping is offered on these hiking shoes, but be sure to allow up to 2-5 business days once shipped. Store pickup is available at select locations. New Balance's 'Comfortable' Fresh Foam Hiking Shoes Are Already $44 Off first appeared on Athlon Sports on Aug 20, 2025 This story was originally reported by Athlon Sports on Aug 20, 2025, where it first appeared.
Business Wire
4 hours ago
- Business Wire
Sonendo Strengthens Leadership Team With Promotion of John McGaugh to Chief Operating Officer
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Sonendo, Inc. ('Sonendo' or the 'Company') (OTC Pink: SONX), a leading dental technology company and developer of the GentleWave® System, today announced the promotion of John McGaugh to Chief Operating Officer. Mr. McGaugh previously held the position of Senior Vice President of Operations. 'Since Sonendo embarked on its strategic reset in early-2024, the Company has stabilized revenue, generated significant leverage in gross margin, and meaningfully lowered total operating expenses, adjusted EBITDA loss and cash burn,' stated Bjarne Bergheim, President and Chief Executive Officer of Sonendo. 'John has been a significant contributor to all those improvements, and we expect he will continue to drive additional operating leverage as the Company continues to execute its plans to achieve profitability. John is a valuable member of the team, and I am excited to see him take on the role of Chief Operating Officer.' In addition to his previous responsibilities overseeing quality, manufacturing, supply chain, and technical services operations, Mr. McGaugh now has oversight of Sonendo's capital and consumables sales teams and commercial operations. Mr. McGaugh has over 20 years overseeing global manufacturing operations. He joined Sonendo in May 2023 and has been instrumental in leading significant operational efficiencies with console assembly and procedure instrument margin contributions. Prior to his time at Sonendo, Mr. McGaugh served as a multi-site operational leader for Abbott Vascular. In addition to his experience at Abbott, Mr. McGaugh has held leadership roles at Boston Scientific and American Medical Systems. About Sonendo Sonendo is a commercial-stage medical technology Company focused on saving teeth from tooth decay, the most prevalent chronic disease globally. Sonendo develops and manufactures the GentleWave® System, an innovative technology platform designed to treat tooth decay by cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The system utilizes a proprietary mechanism of action, which combines procedure fluid optimization, broad-spectrum acoustic energy and advanced fluid dynamics, to debride and disinfect deep regions of the complex root canal system in a less invasive procedure that preserves tooth structure. The clinical benefits of the GentleWave System when compared to conventional methods of root canal therapy include improved clinical outcomes, such as superior cleaning that is independent of root canal complexity and tooth anatomy, high and rapid rates of healing and minimal to no post-operative pain. In addition, the GentleWave System can improve the workflow and economics of dental practices. For more information about Sonendo and the GentleWave System, please visit To find a GentleWave doctor in your area, please visit Forward Looking Statements This news release includes forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the Company's ability to continue to drive additional operating leverage and/or execute its plans to achieve profitability, whether as a result of Mr. McGaugh or otherwise. You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions; speak only as of the date they are made; and, as a result, are subject to risks and uncertainties that may change at any time. Factors that could cause the Company's actual results to differ materially from these forward-looking statements are described in detail in the 'Risk Factors' section of the Company's Annual Report on Form 10-K that was filed with the Securities and Exchange Commission on March 26, 2025. Such filings are available at The Company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent developments, events, or circumstances, except as may be required under applicable securities laws. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
Yahoo
4 hours ago
- Yahoo
Onco360 adds Modeyso™ (dordaviprone) to portfolio of Oncology and Rare Cancer therapies as a National Specialty Pharmacy Provider
LOUISVILLE, Ky., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation's leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Jazz Pharmaceuticals for Modeyso™ (dordaviprone). It is indicated for the treatment of adult and pediatric patients one year of age and older with diffuse midline glioma harboring an H3 K27M-mutation with progressive disease following prior therapy.1 This indication was approved based on five open-label, non-randomized clinical trials conducted in the U.S. (ONC006 [NCT02525692], ONC013 [NCT03295396], ONC014 [NCT03416530], ONC016 [NCT05392374], and ONC018 [NCT03134131]).1 'Onco360 is grateful for the opportunity to add Modeyso™ to our expansive portfolio of cancer and rare disease therapies as the first and only FDA-approved treatment for pediatric and adult patients with diffuse midline glioma,' said Benito Fernandez. 'We are proud and humbled to be part of this innovative treatment in support of patients, caregivers and families impacted by this devastating disease.' Dordaviprone is a protease activator of the mitochondrial caseinolytic protease P (ClpP) and inhibits dopamine D2 receptor (DRD2). In vitro, dordaviprone activates the integrated stress response, induces apoptosis, and alters mitochondrial metabolism, leading to restored histone H3 K27 trimethylation in H3 K27M-mutant diffuse glioma.1 The efficacy of Modeyso was evaluated in an integrated efficacy population of 50 adult and pediatric patients with recurrent H3 K27M-mutant diffuse midline glioma enrolled across five open-label, non-randomized clinical trials.1 The primary outcome was overall response rate (ORR) of 22% (95% CI: 12,36). The trial also demonstrated a duration of response of 10.3 months (95% CI: 7.3, 15.2) with 73% maintaining their response for at least six months and 27% for at least 12 months.1 Dordaviprone demonstrated manageable safety and tolerability adverse events. The most common adverse reactions (≥20 %; all causality) experienced with dordaviprone were fatigue, headache, nausea, vomiting, and musculoskeletal pain.1 Please see the full Prescribing Information for Modeyso. About Onco360 Oncology Pharmacy:Onco360 is the nation's largest independent Oncology Pharmacy and clinical support services company. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. It dispenses nationally through its network of URAC-, and ACHC-accredited Oncology Pharmacies. Onco360 is headquartered in Louisville, Kentucky, and is a flagship specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion, and hospital services company servicing healthcare facilities in the United States. For more information about Onco360, please visit Media Contact: Benito Fernandez, Chief Commercial References:1Modeyso™ (Dordaviprone) [Package Insert]. Palo Alto, CA. Jazz Pharmaceuticals. in to access your portfolio
